The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Oral Antidiabetic Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Oral antidiabetic drugs are medications used to manage blood glucose levels in individuals with type 2 diabetes. They work by improving insulin sensitivity, increasing insulin production, or reducing glucose production in the liver.
The global Oral Antidiabetic Drugs market size is expected to reach US$ 2236.3 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market is mainly driven by the significant applications of Oral Antidiabetic Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Oral Antidiabetic Drugs market. Sulfonylureas, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Meglitinides segment is estimated at % CAGR for the next seven-year period.
The market for oral antidiabetic drugs is driven by the growing prevalence of type 2 diabetes and the need for effective and convenient glucose-lowering medications. The market's growth is also influenced by ongoing research in diabetes therapeutics, leading to the development of new drug classes and combination therapies.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Oral Antidiabetic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Oral Antidiabetic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Oral Antidiabetic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Oral Antidiabetic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Oral Antidiabetic Drugs covered in this report include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer, etc.
The global Oral Antidiabetic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
Abbott
Biocon
Sanofi
Sunpharma
Novartis
Novo Nordisk
Merck
Pfizer
Huadong Medicine Co.,Ltd.
Lepu Medical
Hengrui Medicine
Global Oral Antidiabetic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Oral Antidiabetic Drugs market, Segment by Type:
Sulfonylureas
Meglitinides
Alpha-glucosidase inhibitors
Global Oral Antidiabetic Drugs market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Oral Antidiabetic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Oral antidiabetic drugs are medications used to manage blood glucose levels in individuals with type 2 diabetes. They work by improving insulin sensitivity, increasing insulin production, or reducing glucose production in the liver.
The global Oral Antidiabetic Drugs market size is expected to reach US$ 2236.3 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market is mainly driven by the significant applications of Oral Antidiabetic Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Oral Antidiabetic Drugs market. Sulfonylureas, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Meglitinides segment is estimated at % CAGR for the next seven-year period.
The market for oral antidiabetic drugs is driven by the growing prevalence of type 2 diabetes and the need for effective and convenient glucose-lowering medications. The market's growth is also influenced by ongoing research in diabetes therapeutics, leading to the development of new drug classes and combination therapies.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Oral Antidiabetic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Oral Antidiabetic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Oral Antidiabetic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Oral Antidiabetic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Oral Antidiabetic Drugs covered in this report include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer, etc.
The global Oral Antidiabetic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
Abbott
Biocon
Sanofi
Sunpharma
Novartis
Novo Nordisk
Merck
Pfizer
Huadong Medicine Co.,Ltd.
Lepu Medical
Hengrui Medicine
Global Oral Antidiabetic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Oral Antidiabetic Drugs market, Segment by Type:
Sulfonylureas
Meglitinides
Alpha-glucosidase inhibitors
Global Oral Antidiabetic Drugs market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Oral Antidiabetic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Oral Antidiabetic Drugs
1.1 Oral Antidiabetic Drugs Market Overview
1.1.1 Oral Antidiabetic Drugs Product Scope
1.1.2 Oral Antidiabetic Drugs Market Status and Outlook
1.2 Global Oral Antidiabetic Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Oral Antidiabetic Drugs Market Size by Region (2018-2029)
1.4 Global Oral Antidiabetic Drugs Historic Market Size by Region (2018-2023)
1.5 Global Oral Antidiabetic Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Oral Antidiabetic Drugs Market Size (2018-2029)
1.6.1 North America Oral Antidiabetic Drugs Market Size (2018-2029)
1.6.2 Europe Oral Antidiabetic Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Oral Antidiabetic Drugs Market Size (2018-2029)
1.6.4 Latin America Oral Antidiabetic Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Oral Antidiabetic Drugs Market Size (2018-2029)
2 Oral Antidiabetic Drugs Market by Type
2.1 Introduction
2.1.1 Sulfonylureas
2.1.2 Meglitinides
2.1.3 Alpha-glucosidase inhibitors
2.2 Global Oral Antidiabetic Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Oral Antidiabetic Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Oral Antidiabetic Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Oral Antidiabetic Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Oral Antidiabetic Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Oral Antidiabetic Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Oral Antidiabetic Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Oral Antidiabetic Drugs Revenue Breakdown by Type (2018-2029)
3 Oral Antidiabetic Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Oral Antidiabetic Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Oral Antidiabetic Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Oral Antidiabetic Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Oral Antidiabetic Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Oral Antidiabetic Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Oral Antidiabetic Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Oral Antidiabetic Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Oral Antidiabetic Drugs Revenue Breakdown by Application (2018-2029)
4 Oral Antidiabetic Drugs Competition Analysis by Players
4.1 Global Oral Antidiabetic Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Oral Antidiabetic Drugs as of 2022)
4.3 Date of Key Players Enter into Oral Antidiabetic Drugs Market
4.4 Global Top Players Oral Antidiabetic Drugs Headquarters and Area Served
4.5 Key Players Oral Antidiabetic Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Oral Antidiabetic Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Eli Lilly
5.1.1 Eli Lilly Profile
5.1.2 Eli Lilly Main Business
5.1.3 Eli Lilly Oral Antidiabetic Drugs Products, Services and Solutions
5.1.4 Eli Lilly Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Eli Lilly Recent Developments
5.2 Abbott
5.2.1 Abbott Profile
5.2.2 Abbott Main Business
5.2.3 Abbott Oral Antidiabetic Drugs Products, Services and Solutions
5.2.4 Abbott Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Abbott Recent Developments
5.3 Biocon
5.3.1 Biocon Profile
5.3.2 Biocon Main Business
5.3.3 Biocon Oral Antidiabetic Drugs Products, Services and Solutions
5.3.4 Biocon Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Oral Antidiabetic Drugs Products, Services and Solutions
5.4.4 Sanofi Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 Sunpharma
5.5.1 Sunpharma Profile
5.5.2 Sunpharma Main Business
5.5.3 Sunpharma Oral Antidiabetic Drugs Products, Services and Solutions
5.5.4 Sunpharma Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Sunpharma Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Oral Antidiabetic Drugs Products, Services and Solutions
5.6.4 Novartis Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 Novo Nordisk
5.7.1 Novo Nordisk Profile
5.7.2 Novo Nordisk Main Business
5.7.3 Novo Nordisk Oral Antidiabetic Drugs Products, Services and Solutions
5.7.4 Novo Nordisk Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Novo Nordisk Recent Developments
5.8 Merck
5.8.1 Merck Profile
5.8.2 Merck Main Business
5.8.3 Merck Oral Antidiabetic Drugs Products, Services and Solutions
5.8.4 Merck Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Merck Recent Developments
5.9 Pfizer
5.9.1 Pfizer Profile
5.9.2 Pfizer Main Business
5.9.3 Pfizer Oral Antidiabetic Drugs Products, Services and Solutions
5.9.4 Pfizer Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Pfizer Recent Developments
5.10 Huadong Medicine Co.,Ltd.
5.10.1 Huadong Medicine Co.,Ltd. Profile
5.10.2 Huadong Medicine Co.,Ltd. Main Business
5.10.3 Huadong Medicine Co.,Ltd. Oral Antidiabetic Drugs Products, Services and Solutions
5.10.4 Huadong Medicine Co.,Ltd. Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Huadong Medicine Co.,Ltd. Recent Developments
5.11 Lepu Medical
5.11.1 Lepu Medical Profile
5.11.2 Lepu Medical Main Business
5.11.3 Lepu Medical Oral Antidiabetic Drugs Products, Services and Solutions
5.11.4 Lepu Medical Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Lepu Medical Recent Developments
5.12 Hengrui Medicine
5.12.1 Hengrui Medicine Profile
5.12.2 Hengrui Medicine Main Business
5.12.3 Hengrui Medicine Oral Antidiabetic Drugs Products, Services and Solutions
5.12.4 Hengrui Medicine Oral Antidiabetic Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Hengrui Medicine Recent Developments
6 North America
6.1 North America Oral Antidiabetic Drugs Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Oral Antidiabetic Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Oral Antidiabetic Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Oral Antidiabetic Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Oral Antidiabetic Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Oral Antidiabetic Drugs Market Dynamics
11.1 Oral Antidiabetic Drugs Industry Trends
11.2 Oral Antidiabetic Drugs Market Drivers
11.3 Oral Antidiabetic Drugs Market Challenges
11.4 Oral Antidiabetic Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
